Obesity poses a significant challenge in the medical sphere, particularly among individuals facing elective surgeries, where it’s often linked to various complications. Managing weight before surgery proves to be a crucial step in reducing these risks. Emerging research explores the potential of glucagon-like peptide-1 receptor agonists (GLP-1 RA) as a method for weight loss and its safety in the perioperative phase. While these agents have shown effectiveness in promoting weight reduction, there is still uncertainty surrounding their safety when used around the time of surgery. This study delves into the efficacy and safety of incorporating GLP-1 RA in preoperative care to address these concerns.
Study Methods and Analysis
The researchers conducted a comprehensive review and meta-analysis, scrutinizing data from established databases such as PubMed and Cochrane Library. This search included studies up until March 2025, focusing on adults undergoing elective surgeries who used GLP-1 RA therapies. Key outcomes measured were perioperative safety and preoperative weight reduction. The analysis included both frequentist and Bayesian approaches to ensure robustness in findings. Experts evaluated the studies using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria to judge the evidence’s certainty.
Results and Key Observations
The analysis incorporated data from 21 studies, covering 97,059 patients, with 31.9% utilizing GLP-1 RA preoperatively. Postoperative complications were not notably higher among GLP-1 users, indicated by an odds ratio of 0.78. However, a significant heterogeneity in results was evident. Patients experienced up to a 16.7 kg weight reduction, though the data displayed inconsistent reporting patterns concerning weight loss.
Inferences:
- GLP-1 RA did not raise perioperative complications.
- Preoperative GLP-1 RA use aligns with significant weight reduction.
- Heterogeneity in findings suggests the need for further examination.
- Current evidence suggests low certainty and high risk of bias due to study design.
The implications of GLP-1 RA therapy in preoperative contexts offer an intriguing prospect for weight management without amplifying surgical risks. Although the findings are promising, the evidence’s low certainty underscores the necessity for more rigorous and randomized trials. Such investigations would be instrumental in understanding the cost-effectiveness and strategic incorporation of GLP-1 RAs across varying healthcare systems. Addressing the financial and policy barriers to support such interventions is imperative to enhance global healthcare outcomes, especially given the rising obesity and surgical demands worldwide. Therefore, stakeholders involved in healthcare decision-making should consider prioritizing these areas to foster resilience and adaptability within healthcare infrastructure.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
